MiniMed Group, Inc.
Close on Oct 19, 2026
- Market cap
- $5.00B
- P/E (TTM)
- –
- Dividend yield
- –
About MiniMed
Surgical & Medical Instruments & Apparatus, SIC 3841
MiniMed Group, Inc. develops, manufactures, and sells medical technologies for diabetes care. Its primary offerings comprise automated insulin delivery systems, smart multiple daily injection devices, continuous glucose monitoring sensors, smart insulin pens, and consumable supplies like infusion sets and reservoirs. The company also provides therapy management software and mobile applications that coordinate glucose sensing with algorithmic insulin dosing. MiniMed provides these solutions to people with type 1 and type 2 diabetes requiring intensive insulin treatment, reaching patients through durable medical equipment providers and retail pharmacies upon prescription from healthcare professionals.
The enterprise operates internationally, providing insulin pump solutions to users across more than 80 countries. Its operational infrastructure includes two primary manufacturing and distribution facilities located in California and Puerto Rico, alongside an intellectual property base of over 2,000 patents and patent applications worldwide. MiniMed maintains its corporate headquarters in Northridge, California.
Summary of the business section of MiniMed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MiniMed Group, Inc.
- Headquarters
- Northridge, CA
- Address
- 18000 Devonshire St. 91325
- Phone
- (763) 222-9423
- Employees
- 8,000, Apr 24, 2026
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- MMED
- Other tickers
- MMEDV
- Exchange
- Nasdaq
- IPO date
- Mar 6, 2026
- Shares outstanding
- 281M, Sep 3, 2026
- Filer category
- Non-accelerated filer
- SEC CIK
- 2062583
- CUSIP
- 60365F109
- ISIN
- US60365F1093
- LEI
- 254900MS5BIVZH51VD96
- EIN
- 33-3985981
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Que Dallara | Chief Executive Officer, Director | 884,749 |
| Courtney Nelson Wills | SVP, Gen. Counsel, Corp. Sec. | 136,384 |
| Ali Dianaty | EVP Ch. Prod. & Tech Officer | 315,158 |
| Chad Spooner | EVP, Chief Financial Officer | 362,707 |
| Gillian Chandrasena | SVP, Chief HR Officer | 172,745 |
| John Gyurci | VP, Chief Accounting Officer | 39,941 |
| Christopher Eso | President | – |
| Scott T. Cundy | Director | – |
| David J. Endicott | Director | – |
| Linnea Burman | Director | – |
| Glenn A. Eisenberg | Director | 13,889 |
| Timothy A. Wicks | Director | 13,889 |
| D. Keith Grossman | Director | 13,889 |
| Kevin E. Lofton | Director | 27,778 |
| Matthew R. Walter | Director | – |
| Brett A. Wall | Director | – |
| Robert (Bob) Hopkins | Director | – |
| Laura Mauri | Director | – |
| Brian Sandstrom | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Que Dallara | $8.43M | $4.38M | $3.82M | $71 | $93 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 14, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 9, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 6, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 5, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 30, 2025 | Name change | Name changed from MDT Sub Holdings, Inc. to MiniMed Group, Inc. |